Who Paid My Doc
Matthew Kuiper
Interventional Pain Medicine Portage, MI Doctor of Osteopathy
NPI 1407817349 CMS profile 335391
3770 Glenkerry Ct, Portage, MI 49024
General payments
$2,721
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Matthew Kuiper of Portage, MI is reported in the CMS Open Payments database as having received $2,721 across 110 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 41st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $188 | 8 | |
| 2024 | General | $274 | 3 | |
| 2023 | General | $347 | 5 | |
| 2022 | General | $552 | 29 | |
| 2021 | General | $531 | 28 | |
| 2020 | General | $448 | 22 | |
| 2019 | General | $380 | 15 |
Beside peers
- Matthew Kuiper
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to Matthew Kuiper were reported at $188. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | Matthew Kuiper | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $380 | $684 | $216–$2,079 | $163 |
| 2020 | $448 | $382 | $122–$1,109 | $114 |
| 2021 | $531 | $552 | $167–$1,554 | $132 |
| 2022 | $552 | $605 | $187–$1,924 | $149 |
| 2023 | $347 | $671 | $195–$1,915 | $160 |
| 2024 | $274 | $684 | $206–$1,837 | $164 |
| 2025 | $188 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
909
Drug cost
$20,884
Branded share of claims
21.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Fentanyl | Generic | 49 | $5,202 | |
| Gabapentin | Generic | 199 | $3,009 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 77 | $2,901 | |
| Pregabalin | Generic | 91 | $2,536 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 110 | $1,462 | |
| Tizanidine Hcl | Generic | 61 | $1,276 | |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | Brand | 11 | $1,136 | |
| Duloxetine Hcl | Generic | 52 | $667 | |
| Cyclobenzaprine Hcl | Generic | 52 | $581 | |
| Diclofenac Sodium | Generic | 21 | $452 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 47 billing codesPaid by Medicare
$357,371
Medicare patients
460
Services billed
20,465
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Depression | 35% | |
| Diabetes | 31% | |
| Chronic kidney disease | 29% | |
| Ischemic heart disease | 26% | |
| COPD | 19% | |
| Osteoporosis | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 102 | 4,223 | $429 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 30 | 43 | $216 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 140 | 1,867 | $166 |
| Injection, fentanyl citrate, 0.1 mg J3010 | Office | 88 | 200 | $147 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 34 | 160 | $124 |
| Injection, midazolam hydrochloride, per 1 mg J2250 | Office | 111 | 281 | $30 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
110 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Pain Medicine in Michigan
Ryan Pollina
Interventional Pain Medicine · Saint Clair Shores, MI
Ariel Majjhoo
Interventional Pain Medicine · Monroe, MI
Chad Brummett
Interventional Pain Medicine · Ann Arbor, MI
Anand Thakur
Interventional Pain Medicine · Clinton Township, MI
Evan Peskin
Interventional Pain Medicine · Flint, MI
Richard Ferro
Interventional Pain Medicine · Lansing, MI
Related records
Interventional Pain Medicine in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.